EA023462B1 - Полиморфная форма гидрохлорида придопидина - Google Patents
Полиморфная форма гидрохлорида придопидина Download PDFInfo
- Publication number
- EA023462B1 EA023462B1 EA201490569A EA201490569A EA023462B1 EA 023462 B1 EA023462 B1 EA 023462B1 EA 201490569 A EA201490569 A EA 201490569A EA 201490569 A EA201490569 A EA 201490569A EA 023462 B1 EA023462 B1 EA 023462B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- propylpiperidine
- methanesulfonylphenyl
- crystalline form
- hydrochloride salt
- pridopidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490569A1 EA201490569A1 (ru) | 2014-09-30 |
| EA023462B1 true EA023462B1 (ru) | 2016-06-30 |
Family
ID=47831564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490569A EA023462B1 (ru) | 2011-09-07 | 2012-09-06 | Полиморфная форма гидрохлорида придопидина |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9006445B2 (enExample) |
| EP (1) | EP2753603B1 (enExample) |
| JP (2) | JP6189299B2 (enExample) |
| KR (1) | KR20140075703A (enExample) |
| CN (1) | CN103958469B (enExample) |
| AU (1) | AU2012306386B2 (enExample) |
| BR (1) | BR112014005389A8 (enExample) |
| CA (1) | CA2847736A1 (enExample) |
| EA (1) | EA023462B1 (enExample) |
| ES (1) | ES2639052T3 (enExample) |
| IL (1) | IL231149A0 (enExample) |
| MX (1) | MX343620B (enExample) |
| WO (1) | WO2013034622A1 (enExample) |
| ZA (1) | ZA201402492B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2006040155A1 (en) * | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2012
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en not_active Ceased
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2006040155A1 (en) * | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
Non-Patent Citations (1)
| Title |
|---|
| ANNE ZIMMERMANN ET AL.: "Polymorphs of Pridopidine Hydrochloride", CRYSTAL GROWTH & DESIGN, vol. 12, no. 6, 6 June 2012 (2012-06-06), pages 2961-2968, XP55039965, ISSN: 1528-7483, DOI: 10.1021/cg300185n the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201402492B (en) | 2015-07-29 |
| AU2012306386A1 (en) | 2014-04-17 |
| NZ623344A (en) | 2015-10-30 |
| JP2014525470A (ja) | 2014-09-29 |
| JP6189299B2 (ja) | 2017-08-30 |
| KR20140075703A (ko) | 2014-06-19 |
| ES2639052T3 (es) | 2017-10-25 |
| BR112014005389A2 (pt) | 2017-03-28 |
| EP2753603A1 (en) | 2014-07-16 |
| CN103958469A (zh) | 2014-07-30 |
| MX343620B (es) | 2016-11-11 |
| JP2017206516A (ja) | 2017-11-24 |
| EA201490569A1 (ru) | 2014-09-30 |
| MX2014002731A (es) | 2014-04-30 |
| WO2013034622A1 (en) | 2013-03-14 |
| IL231149A0 (en) | 2014-04-30 |
| CN103958469B (zh) | 2016-04-20 |
| HK1199728A1 (en) | 2015-07-17 |
| BR112014005389A8 (pt) | 2018-04-03 |
| EP2753603B1 (en) | 2017-06-21 |
| AU2012306386B2 (en) | 2017-06-15 |
| US9006445B2 (en) | 2015-04-14 |
| CA2847736A1 (en) | 2013-03-14 |
| US20140315951A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2639052T3 (es) | Forma polimórfica de hidrocloruro de pridopidina | |
| WO2023078424A1 (zh) | Kras突变体抑制剂的晶型、其制备方法及其应用 | |
| CN110494423B (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
| KR101694551B1 (ko) | 로티고틴의 다형 형태 | |
| JP2024164208A (ja) | Ｂｔｋ阻害剤の結晶形態 | |
| CN113754596B (zh) | 一种吉非替尼的共晶体 | |
| EA025561B1 (ru) | Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf | |
| KR20130136544A (ko) | 아고멜라틴의 신규한 결정성 형태 vii, 및 이의 제조 방법 및 용도 및 이를 함유하는 약학적 조성물 | |
| EA023278B1 (ru) | Кристаллический агомелатин (форма-viii), способ его получения, применение и содержащая его фармацевтическая композиция | |
| IL315933A (en) | P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof | |
| US20110301088A1 (en) | Crystalline ezatiostat hydrochloride ansolvate | |
| WO2004076460A1 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
| KR20180129851A (ko) | 나트륨-포도당 연계된 트랜스포터 억제제의 아민 용매화물 및 그의 제조 방법 및 애플리케이션 | |
| JP2013528213A (ja) | エザチオスタットの錠剤製剤 | |
| RU2684278C1 (ru) | Фумарат пиридиламина и его кристаллы | |
| US11787819B2 (en) | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | |
| CN102046637B (zh) | N-[[4-氟-2-(5-甲基-1H-1,2,4-三唑-1-基)苯基]甲基]-4,6,7,9-四氢-3-羟基-9,9-二甲基-4-氧代-嘧啶并[2,1-c][1,4]噁嗪-2-甲酰胺钠盐一水合物的晶体形式 | |
| EA035346B1 (ru) | Соль 4-толуолсульфоновой кислоты и палбоциклиба, способ её получения и её применение в медицине | |
| HK1199728B (en) | Polymorphic form of pridopidine hydrochloride | |
| NZ623344B2 (en) | Polymorphic form of pridopidine hydrochloride | |
| WO2024062421A1 (en) | Bexagliflozin in monohydrate, dihydrate or amorphous forms | |
| BR122026000702A2 (pt) | Formas cristalinas de um inibidor de btk, seu uso e seu processo de produção, composição e combinação farmacêuticas, e kit | |
| WO2018130226A1 (zh) | 利奥西呱的新晶型及其制备方法和用途 | |
| WO2018090360A1 (zh) | 一种三芳基二甲基哌嗪二盐酸盐的多晶型物及其制备方法和应用 | |
| WO1996038439A1 (es) | Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ RU |